Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics: progress, pitfalls and clinical potential for coronary heart disease.

Vascular pharmacology - 1 Feb 2006

Humphries Steve E, Hingorani Aroon

Abstract excerpt

Much has been written about the potential of pharmacogenetic testing to inform therapy based on an individual's genetic makeup, and to decide the most effective choice of available drugs, or to avoid dangerous side effects. Currently, there is little hard data for either in the field of cardiovascular disease. The usual approach has been opportunistic use of drug trials in unrelated patients, and to look for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Cytochrome P-450 CYP2C9
Share to Hemorrhage

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Hydroxymethylglutaryl CoA Reductases

Share to Hyperlipidemias

Share to Pravastatin

Share to Warfarin

Source

Identifiers

PMID: 16359930
DOI: 10.1016/j.vph.2005.10.003

Genes

CETP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics: progress, pitfalls and clinical potential for coronary heart disease.PMID 16359930Read ↗

Cardiovascular pharmacogenetics in the SNP era.Semantic proximity Read ↗

[Cardiovascular pharmacogenomics].Semantic proximity Read ↗

Towards a More Personalized Treatment of Dyslipidemias to Prevent Cardiovascular Disease.Semantic proximity Read ↗

Personalised medicine in hypercholesterolaemia: the role of pharmacogenetics in statin therapy.Semantic proximity Read ↗

Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors.Semantic proximity Read ↗

Cardiovascular pharmacogenetics of antihypertensive and lipid- lowering therapies.Semantic proximity Read ↗

Prognostic Implications of Genetics in Cardiovascular Disease.Semantic proximity Read ↗

Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease managementSemantic proximity Read ↗

[Pharmacogenetics--new perspectives in the treatment of cardiovascular diseases].Semantic proximity Read ↗

Genomics and the prospects of existing and emerging therapeutics for cardiovascular diseases.Semantic proximity Read ↗

Precision medicine in cardiovascular therapeutics: Evaluating the role of pharmacogenetic analysis prior to drug treatmentSemantic proximity Read ↗

Rational Medical Therapy Is the Key to Effective Cardiovascular Disease Prevention.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.